Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

# NCT04240704 Trial phase: 1 Study type: chemotherapy, targeted

Study Start Date

September, 2020

Scientific Title

A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)


The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

For patients with CLL: • Confirmed diagnosis of chronic lymphocytic leukemia (CLL) For patients with NHL: - Histologically confirmed diagnosis of B- or T-cell non-Hodgkins lymphoma (NHL). - Must have a site of disease amenable to biopsy, and be suitable and willing to undergo study required biopsies at screening and during therapy.

Study Design

Primary purpose: Treatment , Allocation: Non-Randomized , Intervention model: Single Group Assignment , Masking: None (Open Label),


Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia

Other Study ID Numbers



Please to see your matching score and connect to trial sponsor